Product Description
Bunazosin, a selective alpha1-adrenoceptor antagonist, an anti-glaucoma drug (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15867947/)
Mechanisms of Action: ADRA1A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Germany | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location:
Company Founding Year: 1941
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00130156 |
DTR-886-401 | P4 |
Completed |
Hypertension |
2008-09-01 |
2019-03-21 |
Treatments |